Karen Brockwell has been promoted to the newly created position of senior director and client team leader of Genentech's new cell culture production facility, CCP-2. She joined Genentech's engineering group as a senior process engineer in 1987. In 1990 she was selected to lead the fermentation operations department of biochemical manufacturing and in 1995 was promoted to director of automation and process engineering. In 1997 Brockwell joined the Vacaville leadership team as director of technology and played a key role in starting up the facility and gaining licensure.
Great Lakes Fine Chemicals has expanded its business development team with the promotion of Ian Trelfa to business development manager. He will be servicing new and existing accounts and will take sole responsibility for managing all outsourced projects and activities.
Dr Pradeep Sanghvi has joined MonoSolRx, a drug delivery company that uses film as a fast-dissolve oral drug delivery platform, as vice president of pharmaceutical development. He previously served as director of pharmaceutical development at oral drug development company Penwest Pharmaceuticals, prior to which he was director of formulations and process development at the fast dissolve tablet company Fuisz Technologies, which was later acquired by Biovail.
Pharmagene has appointed Dr John Brown as a non-executive director, with immediate effect. Most recently Dr Brown was chief executive of biotech company Acambis. He joined Acambis in 1995 and has taken the company from early-stage, through flotation and to profitability. In 1998 he led the $20m acquisition of OraVax Inc, a Boston, US-based vaccines company, followed by a £23m rights issue.
Acambis has appointed Gordon Cameron OBE as chief executive officer of the company. Cameron joined Acambis in 1996 as CFO after a career in investment banking during which he advised Acambis on its listing on the London Stock Exchange. In March 2001, he was appointed to the additional role of President of the company's US division, Acambis Inc and relocated from Cambridge, UK to Cambridge, Massachusetts to manage the rapidly expanding US operations. He was awarded an OBE in the 2004 Queen's New Year's Honours List for services to the British biotechnology industry in the US.